RxDoctor Payments Data

Arleta Kitlas, MD

Nephrology · Bradenton, FLNPI 1891985396

Payments from drug & device makers

$5,644in general payments, 2019–2025

Across 297 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$784
  • GSK$522
  • AbbVie$512
  • Astellas Pharma US Inc$509
  • AstraZeneca$372
  • Lilly USA, LLC$362
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,37495%
  • Education$2705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,644 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$446,990
Medicare patients
1,574
Services billed
4,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$263,572
EliquisApixaban201$244,999
MounjaroTirzepatide179$208,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$89,462
XareltoRivaroxaban77$85,530
JanuviaSitagliptin Phosphate52$70,627
MyrbetriqMirabegron59$56,841
JardianceEmpagliflozin29$37,361
Tresiba Flextouch U-200Insulin Degludec16$33,773
TrulicityDulaglutide17$30,219
FarxigaDapagliflozin Propanediol25$29,895
RybelsusSemaglutide19$27,698
EntrestoSacubitril/Valsartan16$23,130
JanumetSitagliptin Phos/Metformin Hcl13$17,275
Tresiba Flextouch U-100Insulin Degludec35$17,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$784$291,270185 claims
PfizerEliquis, Paxlovid$361$254,576292 claims
Lilly USA, LLCMounjaro, Trulicity$362$238,794196 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$522$113,863134 claims
Johnson & JohnsonXarelto$279$85,53077 claims
Astellas Pharma US IncMyrbetriq$509$56,84159 claims
Boehringer IngelheimJardiance, Stiolto Respimat$15$43,93341 claims
AstraZenecaFarxiga$372$29,89525 claims
NovartisEntresto$47$23,13016 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$14,0581,570 claims
AbbVieSynthroid$512$11,610192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →